Solid Biosciences
Advance the development of its novel gene therapy platform.
loading funding rounds…
Janus Capital Group(exited)
Foresite Capital(exited)
Perceptive Advisors(exited)
RA Capital Management(exited)
Cormorant Asset Management(exited)
Ultragenyx Pharmaceutical(exited)
Pura Vida Investments(exited)
Laurion Capital Management(exited)
CaaS Capital Management(exited)
Biogen(exited)
Janus Henderson Investors(exited)
Deerfield(exited)
EcoR1 Capital(exited)
Boxer Capital(exited)
Waverly Capital(exited)
Xontogeny(exited)
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | (41 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (916 %) | - | - | (509 %) | (1333 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (924 %) | - | - | (530 %) | (1062 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 716 % | - | - | 431 % | 969 % | - | - |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Solid Biosciences
Edit
ACQUISITION by Solid Biosciences Sep 2022